Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Nuvalent raises $50 million for drug-resistant cancer

by Ryan Cross
February 6, 2021 | A version of this story appeared in Volume 99, Issue 5

 

Nuvalent has raised $50 million in series A financing from Deerfield Management to develop small-molecule kinase inhibitors for people whose tumors have developed resistance to existing kinase inhibitors. Nuvalent plans to start a clinical trial of its lead candidate, a ROS1 inhibitor, in non-small-cell lung carcinoma in the second half of 2021. It is also planning a clinical trial of its ALK inhibitor in 2022. Harvard University chemical biologist and organic chemist Matthew Shair founded Nuvalent with Deerfield in 2017.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.